| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-049 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次回购注销的限制性股票数量为 1,334 万股，占回购注销前公司总股 本 481,424,761 股的 2.77%。本次回购注销涉及激励对象 232 人，2024 年限制性 股票激励计划的授予限制性股票的回购价格为 12.42 元/股加上中国人民银行同 期存款利息之和，合计支付的回购金额为人民币 167,497,097.28 元（含中国人民 银行同期存款利息，其中支付回购价款人民币 165,682,800.00 元，支付对应中国 人民银行同期存款利息人民币 1,814,297.28 元）。 2、经中国证券登记结算有限责任公司深圳分公司审核确认，公司本次限制 性股票注销事宜已于 2025 年 9 月 17 日办理完成。本次回购注销完成后，公司总 股本由 481,424, ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-050 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于调整可转换公司债券转股价格的公告 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、债券代码：123064，债券简称：万孚转债 2、转股时间：2021 年 3 月 8 日至 2026 年 8 月 31 日 3、调整前转股价格：26.60 元/股 4、调整后转股价格：27.00 元/股 5、调整后转股价格生效日期：2025 年 9 月 18 日 6、本次可转债价格调整期间，"万孚转债"不停止转股。 一、关于"万孚转债"转股价格调整的依据 经中国证券监督管理委员会"证监许可[2020]1830 号"文同意注册的批复， 公司于 2020 年 9 月 1 日向不特定对象发行了 600 万张可转换公司债券，每张面 值 100 元，发行总额 6.00 亿元。经深交所同意，公司 6.00 亿元可转换公司债券 于 2020 年 9 月 23 日起 ...

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-051 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于控股股东、实际控制人权益变动触及 1%刻度的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次权益变动基本情况 本次权益变动前，公司控股股东、实际控制人李文美先生、王继华女士合计 持有公司合计直接持有公司 147,438,708 股，占公司总股本 30.62%。 经中国证券登记结算有限责任公司深圳分公司审核确认，公司 2024 年股权 激励计划限制性股票需回购注销所涉及激励对象限售股共计 232 名激励对象的 13,340,000 股第一类限制性股票的注销事宜已于 2025 年 9 月 17 日办理完成。使 公司控股股东、实际控制人李文美先生、王继华女士持股比例跨越 1%刻度线。 本次限制性股票回购注销完成后，李文美先生、王继华女士合计持股数量不变仍 为 147,438,708 股，持股比例被动变动为 31.50%，本次权益 ...

Core Viewpoint - Wanfu Bio has signed a strategic agreement with the Ministry of Health of Côte d'Ivoire to enhance the accessibility and affordability of diagnostic products in the ECOWAS region through collaboration in various fields including production, education, research, and application [1] Group 1 - Wanfu Bio will leverage its technology and R&D advantages in the in vitro diagnostic field [1] - The collaboration aims to improve the healthcare system in Côte d'Ivoire and the broader ECOWAS region [1]

人民财讯9月17日电，据万孚生物（300482）消息，近日，万孚生物与科特迪瓦卫生部签署了战略协 议。根据协议，万孚生物将与科特迪瓦医疗体系在产、学、研、用等多个领域展开深入合作。 ...

Core Viewpoint - The article discusses the evolving landscape of the medical device industry in China, highlighting the importance of business development (BD) strategies that go beyond mere numbers to encompass strategic partnerships, market expansion, and technological integration [1][24]. Group 1: Key Trends in Medical Device BD - The primary keywords for the period from July to September include cross-border introduction and global distribution, strategic cooperation, and capital and cross-industry integration [2]. - Companies are accelerating market expansion and ecosystem building through transactions across various fields, including cardiovascular, neuro-intervention, ophthalmology, IVD, and critical care [3]. Group 2: Representative Events - A total of 20 significant events were summarized, showcasing a "multi-line advancement" scenario in the industry [4]. - Notable collaborations include: - Nanjing Jianxin Medical and Heqi Family Office focusing on medical device R&D and wealth management [6]. - Olympus and Xingchenhai Medical signing a global distribution agreement for disposable urology products [6]. - He’s Eye Group and Zeiss China Medical forming a strategic partnership to enhance ophthalmic surgical technology [6]. Group 3: Cross-Border and Global Distribution - Cross-border transactions remain a hot topic, with domestic companies leveraging global markets for growth while foreign giants introduce Chinese innovations [9]. - The partnership between Ruichao Dinkai Group and Beijing Amite focuses on vascular intervention products, marking a new phase in safety standards [7]. Group 4: Strategic Cooperation and Channel Expansion - Strategic cooperation is increasingly focused on building ecosystems rather than single product breakthroughs, with companies forming partnerships in fields like ophthalmology, IVD, and diagnostics [19]. - The collaboration between Wanfu Biological and Beiden Medical aims to match products with non-public medical channels effectively [15]. Group 5: Capital Support and Cross-Industry Integration - Capital is becoming an invisible driver of medical device BD, with partnerships exploring new models for medical device distribution [20]. - The collaboration between Beijing Huamai Supply Chain Management and Hongyi Consulting aims to create a one-stop service for medical device distribution [20]. Group 6: Smart Hospitals and Full-Chain Coordination - The focus on smart hospitals and full-chain coordination is becoming a priority for large enterprises, integrating supply chains, academic promotion, and clinical needs [23]. - Collaborations like that of Ruibo Zehou Technology and China National Pharmaceutical Group aim to develop automated systems for smart hospitals [21]. Conclusion - The medical device industry in China is transitioning from a "single product-driven" phase to a more diversified approach supported by capital, channels, and ecosystems, indicating a long-term growth trajectory [24].

Group 1 - The core viewpoint emphasizes the importance of technology transfer in driving high-quality development in the healthcare industry, highlighting the collaboration between research institutions and pharmaceutical companies as a key factor in medical innovation [1][2][3] - The "Hundred Enterprises and Hundred Hospitals Guangdong Medical Tour" event aims to facilitate the integration of medical and engineering sectors, ensuring precise alignment between clinical needs and research efforts, thereby accelerating the commercialization of scientific achievements [2][8] - The first batch of 133 biomedicine technology transfer achievements was released, showcasing the need for improved conversion rates in the biomedicine sector, which currently faces challenges such as insufficient innovation and immature supply chains [3][4] Group 2 - Guangdong province leads the nation in the number of pharmaceutical and medical device production enterprises, with a total of 8,983 companies and over 1.76 million registered products as of June 2023 [4] - The biomedicine industry in Dongguan has matured over the past decade, with over 500 biopharmaceutical companies established, including notable leaders in various sub-sectors [9][10] - Dongguan's "Songhu Pharmaceutical Port" is positioned as a central hub for biopharmaceutical innovation, aiming to create a comprehensive ecosystem for research, incubation, and industrialization [10][11]

Core Viewpoint - Wanfu Bio has received a medical device registration certificate from the National Medical Products Administration for its nucleic acid test kit for influenza A virus, influenza B virus, and respiratory syncytial virus, marking a significant advancement in respiratory pathogen detection [1] Group 1: Product Development - The nucleic acid test kit is a crucial breakthrough in the field of respiratory pathogen detection, enhancing the company's diagnostic product lineup and strengthening its competitive edge in the in vitro diagnostic sector [1] - On August 21, Wanfu Bio's U-CardDx200 fully automated nucleic acid amplification analyzer received NMPA Class III medical device registration approval, showcasing the company's commitment to innovation in molecular diagnostics [1] Group 2: Technological Innovation - The U-CardDx200 utilizes classic magnetic bead nucleic acid extraction and real-time fluorescence quantitative PCR technology, reducing the total nucleic acid testing time to 15 minutes, effectively functioning as a molecular diagnostic laboratory [1] - This device is designed to meet routine testing needs while also being capable of handling urgent testing demands during peak periods [1]

Core Viewpoint - Wanfu Bio (300482.SZ) has received a medical device registration certificate from the National Medical Products Administration for a nucleic acid detection kit for influenza A virus, influenza B virus, and respiratory syncytial virus (RSV), marking a significant advancement in respiratory pathogen detection [1] Group 1: Product Development - The newly approved product is a key breakthrough in the field of respiratory pathogen detection, which is crucial for addressing acute respiratory infections globally [1] - The product utilizes fluorescent PCR technology, aligning with the company's strategic focus on molecular diagnostics as a core driver of precision medicine [1] Group 2: Competitive Positioning - This new kit will complement the existing product line, enhancing the respiratory disease detection matrix and strengthening the company's overall competitiveness in the in vitro diagnostics sector [1]

特此公告。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）近日 收到国家药品监督管理局颁发的医疗器械注册证，具体信息如下： | 名称 | 注册证号 | 有效期至 | 预期用途 | | | | | --- | --- | --- | --- | --- | --- | --- | | 甲型流感病毒/乙型 | 本试剂盒用于体外定性检测人咽拭子样本中甲型 | 流感病毒/呼吸道合 | 国 | 械 | 注 | 准 | | 流感病毒、乙型流感病毒和呼吸道合胞病毒的核 | 2030/09/04 | 胞病毒核酸检测试剂 | 20253401810 | 酸。 | | | | 盒(荧光 | 法) | PCR | | | | | 甲型流感病毒、乙型流感病毒与呼吸道合胞病毒（RSV）是引起全球急性呼 吸道感染的主要病原体。分子诊断更是作为万孚生物战略布局的前沿技术平台， 是精准医疗的核心驱动力。该产品是公司在呼吸道病原体检测领域的重要突破， 可与现有产品线形成协同，进一步完善呼吸道疾病检测矩阵，强化公司在体外诊 断领域的 ...